Donggu Bio Pharm Begins Development of Peptide Atopic Dermatitis Treatment

Introduction of Immunomodulatory Peptide New Drug Technology from Novacell Technology Co., Ltd.

Donggu Bio Pharm is embarking on the development of a peptide-based new drug for atopic dermatitis.

From left: Shin Junghyun, President of Donggu BioPharm Co., Ltd., and Lee Taehun, CEO of Novacell Technology Co., Ltd. Donggu BioPharm

Donggu Bio Pharm announced on the 11th that it has decided to introduce the technology for the atopic dermatitis biopharmaceutical drug candidate "NCP112" from Novacell Technology Co., Ltd. NCP112 is a pipeline for which the two companies have been conducting joint research through national projects, including the Pan-ministerial National New Drug Development Project.

NCP112 is a therapeutic agent based on "PEPTIROID," an immunomodulatory peptide platform that activates the receptor FPR2, which is involved in mechanisms that resolve inflammation. Novacell Technology Co., Ltd. has completed approval of a phase 2 clinical trial plan in Korea for this candidate.

Through this technology introduction, Donggu Bio Pharm plans to secure a peptide new-drug pipeline for dermatological diseases and seek ways to link it with its existing dermatology prescription drug business.

Lee Taehun, CEO of Novacell Technology Co., Ltd., said, "This technology transfer will serve as an opportunity to confirm the clinical potential of peptide immunotherapeutics." Cho Yongjun, CEO of Donggu Bio Pharm, said, "We will strengthen cooperation in the peptide field to establish a foundation for mid- to long-term growth."

This content was produced with the assistance of AI translation services.